Trial · NCT02964273
Participant flow28
How many started, completed or left each group, period by period.
1 to 20 of 28
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Phase A: Double-blind Period (12 Months) | STARTED | Phase A: Tolvaptan | 48 | |
| Phase A: Double-blind Period (12 Months) | STARTED | Phase A: Placebo | 43 | |
| Phase A: Double-blind Period (12 Months) | STARTED | Phase B: Prior Tolvaptan | 0 | |
| Phase A: Double-blind Period (12 Months) | STARTED | Phase B: Prior Placebo | 0 | |
| Phase A: Double-blind Period (12 Months) | Dense Pharmacokinetic/Pharmacodynamic (PK/PD) Population | Phase A: Tolvaptan | 12 | |
| Phase A: Double-blind Period (12 Months) | Dense Pharmacokinetic/Pharmacodynamic (PK/PD) Population | Phase A: Placebo | 8 | |
| Phase A: Double-blind Period (12 Months) | Dense Pharmacokinetic/Pharmacodynamic (PK/PD) Population | Phase B: Prior Tolvaptan | 0 | |
| Phase A: Double-blind Period (12 Months) | Dense Pharmacokinetic/Pharmacodynamic (PK/PD) Population | Phase B: Prior Placebo | 0 | |
| Phase A: Double-blind Period (12 Months) | COMPLETED | Phase A: Tolvaptan | 44 | |
| Phase A: Double-blind Period (12 Months) | COMPLETED | Phase A: Placebo | 40 | |
| Phase A: Double-blind Period (12 Months) | COMPLETED | Phase B: Prior Tolvaptan | 0 | |
| Phase A: Double-blind Period (12 Months) | COMPLETED | Phase B: Prior Placebo | 0 | |
| Phase A: Double-blind Period (12 Months) | NOT COMPLETED | Phase A: Tolvaptan | 4 | |
| Phase A: Double-blind Period (12 Months) | NOT COMPLETED | Phase A: Placebo | 3 | |
| Phase A: Double-blind Period (12 Months) | NOT COMPLETED | Phase B: Prior Tolvaptan | 0 | |
| Phase A: Double-blind Period (12 Months) | NOT COMPLETED | Phase B: Prior Placebo | 0 | |
| Phase B: Open-label Period (24 Months) | STARTED | Phase A: Tolvaptan | 0 | |
| Phase B: Open-label Period (24 Months) | STARTED | Phase A: Placebo | 0 | |
| Phase B: Open-label Period (24 Months) | STARTED | Phase B: Prior Tolvaptan | 42 | |
| Phase B: Open-label Period (24 Months) | STARTED | Phase B: Prior Placebo | 39 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02964273/flow